Resverlogix Corp.
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
Resverlogix Corp.
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
Resverlogix Corp.
Resverlogix to Host Epigenetics Focused Symposium at The ERA-EDTA Congress in Madrid, Spain
Resverlogix Corp.
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Resverlogix Corp.
Resverlogix Receives Approval From the FDA Cardiovascular and Renal Division to Proceed With a Requested Apabetalone Clinical Trial
Resverlogix Corp.
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
Resverlogix Corp.
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board for Phase 3 Study of Apabetalone (RVX-208)
Resverlogix Corp.
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
Resverlogix Corp.
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
Resverlogix Corp.
Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
Resverlogix Corp.
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
SMART Technologies Inc
SMART Technologies Files Patent Infringement Lawsuit Against CTOUCH in the Netherlands
Resverlogix Corp.
RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus
Hitachi ID Systems, Inc.
Hitachi ID Systems Recognized as Leader in Identity Provisioning by Europe-based Analyst Firm KuppingerCole
12Nächste